The FDA has issued warning letters to 30 telehealth companies for making false or misleading claims about compounded versions of GLP-1 weight-loss drugs, marking what FDA Commissioner Marty Makary described as a new era of enforcement.
According to the agency, some of the warned companies claimed their compounded products were identical to FDA-approved drugs. Others obscured supply chain origins through proprietary branding, making it difficult for consumers to understand where and how the medications were produced.
The action represents the second wave of FDA enforcement targeting the marketing of compounded GLP-1 medications, following an earlier round of warning letters sent in September to manufacturers and sellers. The earlier letters named companies including Eli Lilly, Novo Nordisk, and Hims & Hers.
What happened
On March 3, 2026, the FDA sent warning letters to 30 telehealth companies identified as making false or misleading marketing claims about compounded GLP-1 weight-loss drugs. The letters cited specific marketing practices that the agency said were misleading.
- False sameness claims: Some companies stated or implied that their compounded products were identical to FDA-approved GLP-1 drugs, which the FDA said was inaccurate.
- Hidden supply chain origins: Certain companies used proprietary branding that concealed where the compounded products were manufactured or sourced.
- Enforcement posture: Commissioner Marty Makary publicly framed the action as the beginning of a broader enforcement effort against misleading telehealth marketing of compounded medications.
Warning letters do not constitute a final regulatory action. Recipients are typically given an opportunity to respond to the FDA’s concerns before any further enforcement steps are considered.
Why it matters
The enforcement action signals intensified federal scrutiny of how telehealth platforms advertise and sell compounded GLP-1 weight-loss medications. Compounded drugs are not FDA-approved, and the agency has repeatedly emphasized that compounded versions should not be presented as equivalent to approved products.
The affected groups include telehealth companies, compounding pharmacies operating under Sections 503A and 503B, and consumers seeking GLP-1 treatments. For telehealth platforms, the letters create pressure to review marketing language and supply chain disclosures. For compounding pharmacies, the action reinforces the need for transparency about product origins and differences from approved drugs.
For consumers, the FDA’s concerns highlight the importance of understanding whether a prescribed GLP-1 medication is an FDA-approved drug or a compounded version, and what that distinction means.
This marks the second wave of such warning letters in roughly six months, following the September round sent to manufacturers and sellers of compounded GLP-1 products.
What to watch next
- Whether the 30 warned companies revise their marketing claims and supply chain disclosures in response to the FDA’s letters.
- Whether the FDA escalates any of the warning letters to further enforcement actions, such as injunctions or seizures, against non-compliant companies.
- Whether additional waves of warning letters target other telehealth platforms or compounding pharmacies.
- How telehealth companies and 503A and 503B pharmacies adjust their advertising practices in response to the enforcement signal.
- Whether Congress or state regulators introduce complementary measures addressing compounded GLP-1 marketing.
Sources
Industry information only. Not medical or legal advice.
